Pharma

  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip
    Vaccines

    Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales

    The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu shots in the U.S.

    By • Oct. 24, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA clears return of GSK’s once-withdrawn multiple myeloma drug

    The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market only two years later.

    By • Oct. 23, 2025
  • An illustration of beta amyloid plaques and tau in the brain Explore the Trendline➔
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Alzheimer's disease

    Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

    By BioPharma Dive staff
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi drug acquired in buyout succeeds in rare disease trial

    The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, according to one analyst.

    By • Oct. 22, 2025
  • Calley Means speaks at HLTH 2025
    Image attribution tooltip
    Courtesy of HLTH 2025
    Image attribution tooltip

    Top RFK aide lashes out against healthcare industry for profiting off of illness

    Calley Means stopped short of accusing hospitals, insurers and drug companies from actively working to keep Americans sick, but said it was an "economic fact" that the companies benefit financially when people are ill.

    By Susanna Vogel • Oct. 22, 2025
  • A sign with the logo for the Takeda pharmaceutical company.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Takeda stakes more than $11B on cancer drugs from China

    The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

    By • Oct. 22, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Iambic partners with Jazz; Merck breaks ground on $3B plant

    The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

    By BioPharma Dive staff • Oct. 21, 2025
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Novo’s main shareholder pushes out more than half of company’s board

    The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

    By • Oct. 21, 2025
  • Colleagues working in a lab or data center
    Image attribution tooltip

    AdobeStock/1107050561

    Image attribution tooltip
    Sponsored by Panalgo

    From weeks to minutes: How generative AI transforms pharma data and ROI

    GenAI is changing how pharma teams work — making data accessible, transparent, and actionable.

    By Niyati Parikh, VP, Product Readiness, Panalgo • Oct. 20, 2025
  • Scientific illustration of a migrating breast cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche pill delays tumor progression in closely watched breast cancer study

    Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar hormone-degrading drugs for breast tumors.

    By • Oct. 18, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J claims success in study testing earlier Tecvayli use in multiple myeloma

    The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

    By • Oct. 16, 2025
  • View of the Novartis logo on the Banting 1 building, Novartis Campus Basel.
    Image attribution tooltip
    Courtesy of Novartis
    Image attribution tooltip

    Novartis confirms drug’s benefits in rare kidney disease as competitors loom

    The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time when newer types of medicines are quickly advancing.

    By Kristin Jensen • Oct. 16, 2025
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip

    Novo wagers up to $2.1B on Omeros’ rare disease drug

    The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.

    By • Oct. 15, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

    Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials. 

    By Kristin Jensen • Oct. 15, 2025
  • This image depicts the podcast series cover image for Pearson's BioPharma Dive series, "The Progress Profile: Alzheimer’s Research in Focus"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] The Progress Profile: Alzheimer’s Research in Focus

    Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

    By BioPharma Dive's studioID • Oct. 15, 2025
  • A wall bearing the Johnson & Johnson logo is seen outside of an office building.
    Image attribution tooltip
    Courtesy of Johnson & Johnson
    Image attribution tooltip

    J&J plans to spin out orthopedics business

    CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such as cardiovascular and robotics.

    By Ricky Zipp • Oct. 14, 2025
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Bristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak

    The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body. 

    By • Oct. 10, 2025
  • A 3D illustration of human lungs.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

    The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.

    By • Oct. 8, 2025
  • A photo of FDA CBER Director Peter Marks delivering remarks at a public workshop on March 3, 2020.
    Image attribution tooltip
    Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    Peter Marks, former top FDA vaccine official, joins Eli Lilly

    Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

    By • Oct. 7, 2025
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer

    The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.

    By • Oct. 6, 2025
  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen claims ‘landmark’ study result that could widen heart drug’s use

    In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population. 

    By • Oct. 2, 2025
  • Keytruda Qlex
    Image attribution tooltip
    Courtesy of Merck
    Image attribution tooltip

    Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

    Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.

    By Michael Gibney • Oct. 2, 2025
  • A Takeda logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Takeda, in reversal, abandons cell therapy research

    The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.

    By • Oct. 1, 2025
  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2026

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

    By • Oct. 1, 2025
  • A photo of a man speaking
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip
    Trump administration

    Trump, Pfizer drug pricing deal short on details, possible impact

    A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect those on commercial insurance or who won’t pay out of pocket.

    By • Sept. 30, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Metsera strengthens case for Pfizer buyout with latest study data

    In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

    By • Sept. 30, 2025